dm+d

24556511000001108

Articles

Vonicog alfa

4 January 2016Willfact behaves in the same way as endogenous von Willebrand factor
Search Articles

New Medicines

Willfactvon Willebrand disease

Information

Willfact
New molecular entity
LFB Biopharmaceuticals
Not Known

Development and Regulatory status

Launched
None
None
January 2021
Jan 21Available in UK. Price 1000iu per 10mL vial, 1=£922 [2].
Jan 11Approved in UK for prevention and treatment of haemorrhages or surgical bleeding in von Willebrand disease when desmopressin (DDAVP) treatment alone is ineffective or contraindicated [1].

Category

Willfact behaves in the same way as endogenous von Willebrand factor
Prevalence is as high as 1-2% in the general population on unselected screening. Worldwide incidence is around 125 per million with between 0.5 and 5 per million being severely affected. Most people have mild disease [3].
von Willebrand disease
Intravenous infusion